Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Prostate Cancer

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 54 articles:
HTML format



Single Articles


    November 2022

  1. MRI is more accurate than a PSMA PET/CT scan for prostate cancer diagnosis.
    Cancer. 2022;128:3906.
    PubMed    


  2. RIVIERE P, Kalavacherla S, Banegas MP, Javier-Desloges J, et al
    Patient perspectives of prostate cancer screening vary by race following 2018 guideline changes.
    Cancer. 2022 Nov 7. doi: 10.1002/cncr.34530.
    PubMed     Abstract available


  3. TAN WP, Kotamarti S, Chen E, Mahle R, et al
    Oncological and functional outcomes of men undergoing primary whole gland cryoablation of the prostate: A 20-year experience.
    Cancer. 2022;128:3824-3830.
    PubMed     Abstract available


    October 2022

  4. Men with prostate cancer at higher risk of venous thromboembolism.
    Cancer. 2022;128:3585.
    PubMed    


    September 2022
  5. KOWALCHUK RO, Kim H, Harmsen WS, Jeans EB, et al
    Cost effectiveness of treatment strategies for high risk prostate cancer.
    Cancer. 2022 Sep 7. doi: 10.1002/cncr.34450.
    PubMed     Abstract available


  6. LILLARD JW JR, Moses KA, Mahal BA, George DJ, et al
    Racial disparities in Black men with prostate cancer: A literature review.
    Cancer. 2022 Sep 6. doi: 10.1002/cncr.34433.
    PubMed     Abstract available


    August 2022
  7. HILSCHER M, Roder A, Helgstrand JT, Klemann N, et al
    Risk of prostate cancer and death after benign transurethral resection of the prostate-A 20-year population-based analysis.
    Cancer. 2022 Aug 17. doi: 10.1002/cncr.34407.
    PubMed     Abstract available


    July 2022
  8. FANG AM, Shumaker LA, Martin KD, Jackson JC, et al
    Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions.
    Cancer. 2022 Jul 12. doi: 10.1002/cncr.34355.
    PubMed     Abstract available


  9. O'ROURKE K
    Can multiparametric ultrasound be used for prostate cancer?
    Cancer. 2022;128:2399.
    PubMed    


    June 2022
  10. NNATE DA, Ball J
    Current prostate cancer screening and treatment strategies may not support a holistic nationwide program.
    Cancer. 2022 Jun 1. doi: 10.1002/cncr.34337.
    PubMed     Abstract available


    March 2022
  11. MENDES AA, Lu J, Kaur HB, Zheng SL, et al
    Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer.
    Cancer. 2022 Mar 25. doi: 10.1002/cncr.34190.
    PubMed     Abstract available


  12. O'ROURKE K
    Gut microbiome linked to aggressive prostate cancer.
    Cancer. 2022;128:938.
    PubMed    


    February 2022
  13. MCDONALD AC, Gernand J, Geyer NR, Wu H, et al
    Ambient air exposures to arsenic and cadmium and overall and prostate cancer-specific survival among prostate cancer cases in Pennsylvania, 2004 to 2014.
    Cancer. 2022 Feb 23. doi: 10.1002/cncr.34128.
    PubMed     Abstract available


    January 2022
  14. WITTMANN D, Mehta A, Bober SL, Zhu Z, et al
    TrueNTH Sexual Recovery Intervention for couples coping with prostate cancer: Randomized controlled trial results.
    Cancer. 2022 Jan 5. doi: 10.1002/cncr.34076.
    PubMed     Abstract available


    December 2021
  15. TILBURT JC, Zahrieh D, Pacyna JE, Petereit DG, et al
    Decision aids for localized prostate cancer in diverse minority men: Primary outcome results from a multicenter cancer care delivery trial (Alliance A191402CD).
    Cancer. 2021 Dec 10. doi: 10.1002/cncr.34062.
    PubMed     Abstract available


  16. HAY A
    Stockholm3 tests improve prostate cancer screening.
    Cancer. 2021;127:4328-4329.
    PubMed    


    November 2021
  17. JAVIER-DESLOGES J, Nelson TJ, Murphy JD, McKay RR, et al
    Disparities and trends in the participation of minorities, women, and the elderly in breast, colorectal, lung, and prostate cancer clinical trials.
    Cancer. 2021 Nov 22. doi: 10.1002/cncr.33991.
    PubMed     Abstract available


  18. LIM JE, Huang J, Mnnist S, Weinstein SJ, et al
    Hair dye use and prostate cancer risk: A prospective analysis in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study cohort.
    Cancer. 2021 Nov 19. doi: 10.1002/cncr.34035.
    PubMed     Abstract available


    September 2021
  19. KIRK PS, Zhu K, Zheng Y, Newcomb LF, et al
    Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer.
    Cancer. 2021 Sep 13. doi: 10.1002/cncr.33911.
    PubMed     Abstract available


    August 2021
  20. PATEL HD, Koehne EL, Shea SM, Bhanji Y, et al
    Risk of prostate cancer for men with prior negative biopsies undergoing magnetic resonance imaging compared with biopsy-naive men: A prospective evaluation of the PLUM cohort.
    Cancer. 2021 Aug 24. doi: 10.1002/cncr.33875.
    PubMed     Abstract available


  21. EZENWANKWO EF, Nnaji CA
    Prostate cancer and the added burden of COVID-19 in sub-Saharan Africa: Rethinking regional priorities for responsive and data-driven cancer control programs.
    Cancer. 2021 Aug 23. doi: 10.1002/cncr.33887.
    PubMed    


  22. GARLAND SN, Savard J, Eisel SL, Wassersug RJ, et al
    A 2-year prospective analysis of insomnia as a mediator of the relationship between androgen deprivation therapy and perceived cognitive function in men with prostate cancer.
    Cancer. 2021 Aug 19. doi: 10.1002/cncr.33850.
    PubMed     Abstract available


  23. NIERENGARTEN MB
    Health literacy may determine treatment choice for favorable-risk prostate cancer: Results from a new trial show that men with low health literacy are less likely to choose active surveillance for prostate cancer after genomic testing.
    Cancer. 2021;127:2825-2826.
    PubMed    


  24. NECCHI A, Cucchiara V, Grivas P, Bratslavsky G, et al
    Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer.
    Cancer. 2021 Aug 11. doi: 10.1002/cncr.33865.
    PubMed     Abstract available


  25. MEISSNER VH, Olze L, Schiele S, Ankerst DP, et al
    Fear of cancer recurrence and disease progression in long-term prostate cancer survivors after radical prostatectomy: A longitudinal study.
    Cancer. 2021 Aug 6. doi: 10.1002/cncr.33836.
    PubMed     Abstract available


  26. BERGEROT CD, Williams SB, Klaassen Z
    Fear of cancer recurrence among patients with localized prostate cancer.
    Cancer. 2021 Aug 6. doi: 10.1002/cncr.33837.
    PubMed    


  27. COURTNEY PT, Deka R, Kotha NV, Cherry DR, et al
    Active surveillance for intermediate-risk prostate cancer in African American and non-Hispanic White men.
    Cancer. 2021 Aug 4. doi: 10.1002/cncr.33824.
    PubMed     Abstract available


    July 2021
  28. SERAPHIN TP, Joko-Fru WY, Hammerl L, Griesel M, et al
    Presentation, patterns of care, and outcomes of patients with prostate cancer in sub-Saharan Africa: A population-based registry study.
    Cancer. 2021 Jul 30. doi: 10.1002/cncr.33818.
    PubMed     Abstract available


  29. GREENBERG SA, Washington SL 3rd
    The state of our understanding of prostate cancer in sub-Saharan Africa.
    Cancer. 2021 Jul 30. doi: 10.1002/cncr.33815.
    PubMed    


  30. FERRARO S, Rossi RS, Biganzoli EM
    Benefit-harm ratio of the diagnostic workup in patients with prostate cancer of Gleason score from 9 to 10.
    Cancer. 2021 Jul 23. doi: 10.1002/cncr.33811.
    PubMed    


  31. KIM DW, Tilki D, D'Amico AV
    Reply to Benefit-harm ratio of the diagnostic workup in patients with prostate cancer and a Gleason score of 9 to 10.
    Cancer. 2021 Jul 23. doi: 10.1002/cncr.33813.
    PubMed    


  32. PRINTZ C
    Prostate cancer in Black men responds better to immunotherapy.
    Cancer. 2021;127:2389.
    PubMed    


  33. KIM DW, Chen MH, Wu J, Huland H, et al
    Prostate-specific antigen levels of 4 ng/mL and risk of prostate cancer-specific mortality in men with biopsy Gleason score 9 to 10 prostate cancer.
    Cancer. 2021;127:2222-2228.
    PubMed     Abstract available


  34. PATEL DC, He H, Berry MF, Yang CJ, et al
    Cancer diagnoses and survival rise as 65-year-olds become Medicare-eligible.
    Cancer. 2021;127:2302-2310.
    PubMed     Abstract available


    June 2021
  35. RUDE T, Walter D, Ciprut S, Kelly MD, et al
    Interaction between race and prostate cancer treatment benefit in the Veterans Health Administration.
    Cancer. 2021 Jun 29. doi: 10.1002/cncr.33643.
    PubMed     Abstract available


  36. QUINN TP, Sanda MG, Howard DH, Patil D, et al
    Disparities in magnetic resonance imaging of the prostate for traditionally underserved patients with prostate cancer.
    Cancer. 2021 Jun 17. doi: 10.1002/cncr.33518.
    PubMed     Abstract available


  37. MCMAHON GC, Leapman MS
    A disease by any other name: Effects of cancer grading nomenclature on perception of prostate cancer risk.
    Cancer. 2021 Jun 3. doi: 10.1002/cncr.33619.
    PubMed    


  38. HUDNALL MT, Desai AS, Tsai KP, Weiner AB, et al
    It's all in the name: Does nomenclature for indolent prostate cancer impact management and anxiety?
    Cancer. 2021 Jun 3. doi: 10.1002/cncr.33621.
    PubMed     Abstract available


  39. HOWARD DH, Quek RGW, Fox KM, Arondekar B, et al
    The value of new drugs for advanced prostate cancer.
    Cancer. 2021 Jun 1. doi: 10.1002/cncr.33662.
    PubMed     Abstract available


  40. PARIKH RB, Gallo JJ, Wong YN, Robinson KW, et al
    Long-term depression incidence and associated mortality among African American and White prostate cancer survivors.
    Cancer. 2021 Jun 1. doi: 10.1002/cncr.33656.
    PubMed     Abstract available


    May 2021
  41. HUNT TC, Ambrose JP, Haaland B, Kawamoto K, et al
    Decision fatigue in low-value prostate cancer screening.
    Cancer. 2021 May 27. doi: 10.1002/cncr.33644.
    PubMed     Abstract available


  42. COLE AP, Herzog P, Iyer HS, Marchese M, et al
    Racial differences in the treatment and outcomes for prostate cancer in Massachusetts.
    Cancer. 2021 May 17. doi: 10.1002/cncr.33564.
    PubMed     Abstract available


  43. GEORGE DJ, Halabi S, Heath EI, Sartor AO, et al
    A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.
    Cancer. 2021 May 5. doi: 10.1002/cncr.33589.
    PubMed     Abstract available


    April 2021
  44. BUTLER SS, Mahal BA, Moslehi JJ, Nohria A, et al
    Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: A secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Controlled Trial.
    Cancer. 2021 Apr 27. doi: 10.1002/cncr.33486.
    PubMed     Abstract available


  45. BAUER JE
    Prostate cancer survivorship, deaths, and health care management.
    Cancer. 2021 Apr 21. doi: 10.1002/cncr.33588.
    PubMed    


  46. WEINER AB, Li EV, Desai AS, Press DJ, et al
    Cause of death during prostate cancer survivorship: A contemporary, US population-based analysis.
    Cancer. 2021 Apr 21. doi: 10.1002/cncr.33584.
    PubMed     Abstract available


  47. ONDERDONK BE, Dorn PL, Martinez C, Arif F, et al
    A prospective clinical and transcriptomic feasibility study of oral-only hormonal therapy with radiation for unfavorable prostate cancer in men 70 years of age and older or with comorbidity.
    Cancer. 2021 Apr 21. doi: 10.1002/cncr.33556.
    PubMed     Abstract available


  48. BITTERMAN DS, Chen MH, Wu J, Renshaw AA, et al
    Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer-specific mortality.
    Cancer. 2021 Apr 6. doi: 10.1002/cncr.33543.
    PubMed     Abstract available


  49. ALIBHAI SMH, Breunis H, Hansen AR, Gregg R, et al
    Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen-receptor-targeted therapy for metastatic castration-resistant prostate cancer.
    Cancer. 2021 Apr 2. doi: 10.1002/cncr.33523.
    PubMed     Abstract available


  50. IYER HS, Gomez SL, Chen JT, Trinh QD, et al
    Trends in mortality among Black and White men with prostate cancer in Massachusetts and Pennsylvania: Race and neighborhood socioeconomic position.
    Cancer. 2021 Apr 2. doi: 10.1002/cncr.33506.
    PubMed     Abstract available


    February 2021
  51. NABI J, Tully KH, Cole AP, Marchese M, et al
    Access denied: The relationship between patient insurance status and access to high-volume hospitals.
    Cancer. 2021;127:577-585.
    PubMed     Abstract available


    January 2021
  52. NGUYEN DD, Trinh QD, Cole AP, Kilbridge KL, et al
    Impact of health literacy on shared decision making for prostate-specific antigen screening in the United States.
    Cancer. 2021;127:249-256.
    PubMed     Abstract available


  53. LAUTZ TB, Chi YY, Li M, Wolden SL, et al
    Benefit of delayed primary excision in rhabdomyosarcoma: A report from the Children's Oncology Group.
    Cancer. 2021;127:275-283.
    PubMed     Abstract available


    June 2020
  54. PRINTZ C
    Price transparency still an issue for cancer center costs.
    Cancer. 2020;126:2733.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: